Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TScan TherapeuticsTCRX -3.15%44 Current Ratio is 3.37 as of Jun. 2026, which is 53% below its 10-year median of 7.12. GuruFocus rates TCRX with a GF Score™ of 44/100 and a GF Value™ of $1.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 1,410 Biotechnology companies, TScan Therapeutics ranks worse than 55.39% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. TScan Therapeutics's current ratio for the quarter that ended in Jun. 2026 was 3.37.
TScan Therapeutics has a current ratio of 3.37. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for TScan Therapeutics's Current Ratio or its related term are showing as below:
TCRX'
s Current Ratio Range Over the Past 10 Years
Min: 2.09 Med: 7.12 Max: 17.69
Current: 3.37
During the past 7 years, TScan Therapeutics's highest Current Ratio was 17.69. The lowest was 2.09. And the median was 7.12.
TCRX's Current Ratio is ranked worse than 55.39% of 1410
companies
in the Biotechnology industry
Industry Median: 3.95
vs TCRX: 3.37
TScan Therapeutics (NAS:TCRX) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
TScan Therapeutics Current Ratio Related Terms
TScan Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for TScan Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TCRX vs MCRB, HYPD, ELOX: Current Ratio Comparison
For the Biotechnology subindustry, TScan Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TScan Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where TScan Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TScan Therapeutics (TCRX) has a Current Ratio of 3.37 as of Jun. 2026. This is 53% below median its historical median of 7.12. Over the past decade, TScan Therapeutics' Current Ratio has ranged from 2.09 to 17.69. According to the industry distribution chart, TScan Therapeutics ranks #781 out of 1410 companies in the Biotechnology industry, placing it in the top 55.4%.
Is TScan Therapeutics' Current Ratio too high?
TScan Therapeutics' current Current Ratio of 3.37 is 53% below median its 10-year median of 7.12. Over the past 10 years, this metric has ranged from a low of 2.09 to a high of 17.69. The Biotechnology industry median Current Ratio is 3.95. TScan Therapeutics' value of 3.37 is 14.7% below this industry median. Based on the distribution chart, TScan Therapeutics ranks #781 out of 1410 companies in the Biotechnology industry, which is below the industry midpoint. Overall, TScan Therapeutics has a GF Score™ of 44/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TScan Therapeutics' Current Ratio compare to MCRB and HYPD?
According to the Biotechnology industry distribution chart, TScan Therapeutics ranks #781 out of 1410 companies for Current Ratio. This places TScan Therapeutics in the lower half of its industry. The industry median Current Ratio is 3.95. TScan Therapeutics' value of 3.37 is 14.7% below this benchmark. Historically, TScan Therapeutics' own Current Ratio has ranged from 2.09 to 17.69 over the past decade. While the company's 10-year median is 7.12 vs. the industry median of 3.95, TScan Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.95, based on 1,410 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TScan Therapeutics's current Current Ratio of 3.37 is 14.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TScan Therapeutics's current Current Ratio is 3.37, which is 53% below median its own 10-year median of 7.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TScan Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, TScan Therapeutics (TCRX) is currently considered Possible Value Trap. The stock's GF Value™ is $1.32, compared to a current price of $0.73 — trading 44.7% below its estimated fair value. The current Current Ratio is 3.37, which is 53% below median its 10-year median of 7.12 and 14.7% below the Biotechnology industry median of 3.95. TScan Therapeutics' overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For TScan Therapeutics (TCRX), the current Current Ratio is 3.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TScan Therapeutics (TCRX) Overvalued in 2026?
Based on GuruFocus' analysis, TScan Therapeutics stock appears to be undervalued.
The current stock price of $0.73 is trading 44.7% below its estimated GF Value™ of $1.32.
GuruFocus considers TScan Therapeutics to be Possible Value Trap.
Key valuation signals for TCRX:
Current Ratio: 3.37 (53% below median its 10-year median of 7.12)
GF Value™: $1.32 vs. price of $0.73 (44.7% below fair value)
Industry Position: 14.7% below the Biotechnology median (#781 of 1410)
No single metric tells the full story. See the TCRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
44GF Score
Get the complete analysis for TCRX
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TCRX has been successfully added to your 
